183 related articles for article (PubMed ID: 31974273)
21. Control of tumor-associated macrophage alternative activation by macrophage migration inhibitory factor.
Yaddanapudi K; Putty K; Rendon BE; Lamont GJ; Faughn JD; Satoskar A; Lasnik A; Eaton JW; Mitchell RA
J Immunol; 2013 Mar; 190(6):2984-93. PubMed ID: 23390297
[TBL] [Abstract][Full Text] [Related]
22. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
23. MK2 Regulates Macrophage Chemokine Activity and Recruitment to Promote Colon Tumor Growth.
Phinney BB; Ray AL; Peretti AS; Jerman SJ; Grim C; Pinchuk IV; Beswick EJ
Front Immunol; 2018; 9():1857. PubMed ID: 30298062
[TBL] [Abstract][Full Text] [Related]
24. Activation of NF-κB and respiratory burst following Aspergillus fumigatus stimulation of macrophages.
Sun H; Xu XY; Tian XL; Shao HT; Wu XD; Wang Q; Su X; Shi Y
Immunobiology; 2014 Jan; 219(1):25-36. PubMed ID: 23886693
[TBL] [Abstract][Full Text] [Related]
25. MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis.
Cook RS; Jacobsen KM; Wofford AM; DeRyckere D; Stanford J; Prieto AL; Redente E; Sandahl M; Hunter DM; Strunk KE; Graham DK; Earp HS
J Clin Invest; 2013 Aug; 123(8):3231-42. PubMed ID: 23867499
[TBL] [Abstract][Full Text] [Related]
26. Psoralidin inhibits LPS-induced iNOS expression via repressing Syk-mediated activation of PI3K-IKK-IκB signaling pathways.
Chiou WF; Don MJ; Liao JF; Wei BL
Eur J Pharmacol; 2011 Jan; 650(1):102-9. PubMed ID: 20951127
[TBL] [Abstract][Full Text] [Related]
27. Antitumor activity of orally administered maitake α-glucan by stimulating antitumor immune response in murine tumor.
Masuda Y; Nakayama Y; Tanaka A; Naito K; Konishi M
PLoS One; 2017; 12(3):e0173621. PubMed ID: 28278221
[TBL] [Abstract][Full Text] [Related]
28. Quercetin disrupts tyrosine-phosphorylated phosphatidylinositol 3-kinase and myeloid differentiation factor-88 association, and inhibits MAPK/AP-1 and IKK/NF-κB-induced inflammatory mediators production in RAW 264.7 cells.
Endale M; Park SC; Kim S; Kim SH; Yang Y; Cho JY; Rhee MH
Immunobiology; 2013 Dec; 218(12):1452-67. PubMed ID: 23735482
[TBL] [Abstract][Full Text] [Related]
29. Macrophages confer resistance to PI3K inhibitor GDC-0941 in breast cancer through the activation of NF-κB signaling.
Usman MW; Gao J; Zheng T; Rui C; Li T; Bian X; Cheng H; Liu P; Luo F
Cell Death Dis; 2018 Jul; 9(8):809. PubMed ID: 30042442
[TBL] [Abstract][Full Text] [Related]
30. EZH2 Inhibitor GSK126 Suppresses Antitumor Immunity by Driving Production of Myeloid-Derived Suppressor Cells.
Huang S; Wang Z; Zhou J; Huang J; Zhou L; Luo J; Wan YY; Long H; Zhu B
Cancer Res; 2019 Apr; 79(8):2009-2020. PubMed ID: 30737232
[TBL] [Abstract][Full Text] [Related]
31. HMGB1 mediates Aspergillus fumigatus-induced inflammatory response in alveolar macrophages of COPD mice via activating MyD88/NF-κB and syk/PI3K signalings.
Zhang P; Xin X; Fang L; Jiang H; Xu X; Su X; Shi Y
Int Immunopharmacol; 2017 Dec; 53():125-132. PubMed ID: 29078091
[TBL] [Abstract][Full Text] [Related]
32. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.
Liao C; Hsu J; Kim Y; Hu DQ; Xu D; Zhang J; Pashine A; Menke J; Whittard T; Romero N; Truitt T; Slade M; Lukacs C; Hermann J; Zhou M; Lucas M; Narula S; DeMartino J; Tan SL
Arthritis Res Ther; 2013 Oct; 15(5):R146. PubMed ID: 24286216
[TBL] [Abstract][Full Text] [Related]
33. Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer.
Gunderson AJ; Kaneda MM; Tsujikawa T; Nguyen AV; Affara NI; Ruffell B; Gorjestani S; Liudahl SM; Truitt M; Olson P; Kim G; Hanahan D; Tempero MA; Sheppard B; Irving B; Chang BY; Varner JA; Coussens LM
Cancer Discov; 2016 Mar; 6(3):270-85. PubMed ID: 26715645
[TBL] [Abstract][Full Text] [Related]
34. PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment.
Piddock RE; Loughran N; Marlein CR; Robinson SD; Edwards DR; Yu S; Pillinger GE; Zhou Z; Zaitseva L; Auger MJ; Rushworth SA; Bowles KM
Blood Cancer J; 2017 Mar; 7(3):e539. PubMed ID: 28282033
[TBL] [Abstract][Full Text] [Related]
35. Isoliquiritigenin Attenuates UUO-Induced Renal Inflammation and Fibrosis by Inhibiting Mincle/Syk/NF-Kappa B Signaling Pathway.
Liao Y; Tan RZ; Li JC; Liu TT; Zhong X; Yan Y; Yang JK; Lin X; Fan JM; Wang L
Drug Des Devel Ther; 2020; 14():1455-1468. PubMed ID: 32341639
[TBL] [Abstract][Full Text] [Related]
36. Anti-inflammatory actions of Syk inhibitors in macrophages involve non-specific inhibition of toll-like receptors-mediated JNK signaling pathway.
Lin YC; Huang DY; Chu CL; Lin WW
Mol Immunol; 2010 Apr; 47(7-8):1569-78. PubMed ID: 20138367
[TBL] [Abstract][Full Text] [Related]
37. Gefitinib inhibits M2-like polarization of tumor-associated macrophages in Lewis lung cancer by targeting the STAT6 signaling pathway.
Tariq M; Zhang JQ; Liang GK; He QJ; Ding L; Yang B
Acta Pharmacol Sin; 2017 Nov; 38(11):1501-1511. PubMed ID: 29022575
[TBL] [Abstract][Full Text] [Related]
38. A multifunctional chimeric chaperone serves as a novel immune modulator inducing therapeutic antitumor immunity.
Yu X; Guo C; Yi H; Qian J; Fisher PB; Subjeck JR; Wang XY
Cancer Res; 2013 Apr; 73(7):2093-103. PubMed ID: 23333935
[TBL] [Abstract][Full Text] [Related]
39. SYK regulates macrophage MHC-II expression via activation of autophagy in response to oxidized LDL.
Choi SH; Gonen A; Diehl CJ; Kim J; Almazan F; Witztum JL; Miller YI
Autophagy; 2015; 11(5):785-95. PubMed ID: 25946330
[TBL] [Abstract][Full Text] [Related]
40. Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models.
Peng X; Hou P; Chen Y; Dai Y; Ji Y; Shen Y; Su Y; Liu B; Wang Y; Sun D; Jiang Y; Zha C; Xie Z; Ding J; Geng M; Ai J
J Exp Clin Cancer Res; 2019 Aug; 38(1):372. PubMed ID: 31438996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
